Imitrex Instant

Sumatriptan, the active ingredient in Imitrex Instant, is a Triptan presented as a 10 mg sublingual tablet for oral (sublingual) use. It treats acute migraine attacks, including migraine with aura, in adults and is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Imitrex Instant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan is a selective serotonin (5‑HT1B/1D) receptor agonist used in the acute management of migraine.

Migraine without aura: provides rapid relief of headache and associated symptoms. Migraine with aura: aborts the headache phase after aura resolves. Acute migraine in adults: reduces pain intensity and improves functional ability during an attack.

Common Side Effects: - Chest discomfort or tightness - Throat constriction - Tingling, numbness or paresthesia - Dizziness or light‑headedness - Nausea or abdominal discomfort - Flushing or warmth sensation

Serious or Rare Side Effects: - Serotonin syndrome, especially with serotonergic drugs - Severe coronary vasospasm or myocardial ischemia - Stroke or transient ischemic attack - Allergic reactions including anaphylaxis - Hypertensive crisis - Severe arrhythmias

Before using Imitrex Instant, consider the following precautions.

Cardiovascular disease: avoid use in patients with known coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. Concomitant serotonergic drugs: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. Age: not established in children; generally not recommended for patients under 18. Drug interactions: review patient medication list for ergot alkaloids and potent CYP3A4 modulators. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Sumatriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO‑A inhibitors (e.g., phenelzine): risk of severe hypertension and serotonin syndrome. - SSRIs, SNRIs, tricyclic antidepressants: increased risk of serotonin syndrome. - Ergot alkaloids (e.g., ergotamine): may cause additive vasospasm.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate hypotensive effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic efficacy.